NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
1.700
0.00 (0.00%)
Mar 9, 2026, 2:16 PM EDT - Market open
NRx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 11.09 | 13.51 | 14.22 | 27.31 | 74.94 | 11.44 | |
| Research & Development | 4.26 | 6.2 | 13.37 | 17.03 | 20.26 | 10.63 | |
| Other Operating Expenses | - | - | - | - | -0.77 | -10.16 | |
| Operating Expenses | 15.37 | 19.7 | 27.59 | 44.34 | 94.43 | 11.9 | |
| Operating Income | -15.23 | -19.7 | -27.59 | -44.34 | -94.43 | -11.9 | |
| Interest Expense | - | -0.23 | -0.12 | - | -0.02 | -0.06 | |
| Interest & Investment Income | 0.01 | 0.04 | 0.49 | 0.25 | - | - | |
| Other Non Operating Income (Expenses) | -12.34 | -3.78 | 0.02 | 0.26 | 1.69 | -0.03 | |
| EBT Excluding Unusual Items | -27.56 | -23.67 | -27.19 | -43.83 | -92.76 | -11.98 | |
| Other Unusual Items | -10.5 | -1.45 | -2.96 | 4.08 | -0.31 | -39.79 | |
| Pretax Income | -38.06 | -25.13 | -30.15 | -39.75 | -93.06 | -51.78 | |
| Net Income | -38.06 | -25.13 | -30.15 | -39.75 | -93.06 | -51.78 | |
| Preferred Dividends & Other Adjustments | - | - | 0.01 | - | - | - | |
| Net Income to Common | -38.06 | -25.13 | -30.16 | -39.75 | -93.06 | -51.78 | |
| Shares Outstanding (Basic) | 17 | 11 | 8 | 7 | 5 | 3 | |
| Shares Outstanding (Diluted) | 17 | 11 | 8 | 7 | 5 | 3 | |
| Shares Change (YoY) | 79.43% | 40.50% | 15.20% | 40.17% | 36.90% | 220.58% | |
| EPS (Basic) | -2.21 | -2.36 | -3.98 | -6.04 | -19.84 | -15.11 | |
| EPS (Diluted) | -2.21 | -2.36 | -3.98 | -6.04 | -74.40 | -15.11 | |
| Free Cash Flow | -12.5 | -10.64 | -21.66 | -39.77 | -37.71 | -2.27 | |
| Free Cash Flow Per Share | -0.73 | -1.00 | -2.86 | -6.05 | -8.04 | -0.66 | |
| EBITDA | -15.2 | -19.7 | -27.58 | -44.33 | -94.43 | -11.9 | |
| D&A For EBITDA | 0.03 | 0.01 | 0.01 | 0 | 0 | 0 | |
| EBIT | -15.23 | -19.7 | -27.59 | -44.34 | -94.43 | -11.9 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.